보고서 요약(국문)

개요
전 세계 인슐린 바이오시밀러 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 기록하며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
바이오시밀러는 오리지널 생물학적 의약품과 동일한 효능을 가지며, 해당 생물학적 의약품의 특허가 만료된 후 개발됩니다. 바이오시밀러 인슐린은 오리지널 인슐린의 생물학적 복제본으로, 개발 및 활용에 대한 관심이 증가하고 있습니다. 바이오시밀러 인슐린은 오리지널 의약품에 비해 가격이 저렴하여 영국 국민보건서비스(NHS)에 공급량 및 치료 비용 측면에서 긍정적인 전망을 제공합니다.
시장 동향: 성장 동인 및 제약 요인
당뇨병 환자 증가
전 세계 시장은 당뇨병 환자 증가로 인해 예측 기간 동안 성장이 가속화될 것으로 예상됩니다. 세계보건기구(WHO)에 따르면 전 세계적으로 약 4억 2,200만 명이 당뇨병을 앓고 있으며, 이들 대부분은 저소득 및 중소득 국가에 거주하고 있습니다. 또한 매년 150만 명 이상이 당뇨병으로 인해 사망하고 있습니다. 당뇨병 환자 수와 유병률은 지난 수십 년 동안 꾸준히 증가해 왔습니다. 국제당뇨병연맹(IDF)은 2045년까지 성인 8명 중 1명꼴인 약 7억 8,300만 명이 당뇨병을 앓게 될 것으로 예측하며, 이는 46% 증가한 수치입니다. 당뇨병 환자의 90% 이상은 제2형 당뇨병으로, 사회경제적, 인구통계학적, 환경적, 유전적 요인에 의해 발생합니다. 호주당뇨병협회(Diabetes Australia)는 당뇨병을 전 세계적으로 가장 빠르게 증가하는 만성 질환으로 규정하고 있습니다. 제2형 당뇨병 환자 수는 각국에서 증가하고 있으며, 2021년에는 전 세계적으로 670만 명이 당뇨병으로 사망했습니다.
이러한 요인 외에도 고령 인구 증가와 연구 활동 확대는 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다.
인슐린 부작용
그러나 인슐린 바이오시밀러의 세계 시장 성장은 부작용으로 인해 예측 기간 동안 저해될 것으로 예상됩니다. 인슐린의 일반적인 부작용으로는 저혈당(혈당 수치 저하), 주사 부위 알레르기, 체중 증가 등이 있습니다. 드물게 발생하는 부작용으로는 지방이영양증(비정상적인 지방 분포)과 팔다리 부종이 있습니다. 또한, 엄격한 규제 기관과 높은 치료 비용 또한 예측 기간 동안 세계 시장 성장을 둔화시키는 요인으로 작용합니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
세계 인슐린 바이오시밀러 시장은 제품, 적응증, 유통 채널 및 지역별로 세분화됩니다.
장기 지속형 인슐린 바이오시밀러 제품 유형 부문이 시장을 주도할 것으로 예상됩니다.
예측 기간 동안 장기 지속형 인슐린 바이오시밀러 부문은 제품 출시 및 승인 증가로 인해 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 일라이 릴리 앤 컴퍼니는 2023년 4월 미국 시장에 인슐린 글라진 바이오시밀러인 레즈보글라(Rezvoglar, 인슐린 글라진-AGLR)를 출시하여 미국 당뇨병 환자들이 상업적으로 이용할 수 있게 된 두 번째 상호 교환 가능한 인슐린 바이오시밀러가 되었습니다. 또한, 2022년 11월 FDA는 2021년 12월에 승인된 란투스(Lantus, 인슐린 글라진)의 바이오시밀러인 레즈보글라에 대해 상호 교환성 지정을 승인하여 의사의 허가 없이 약국에서 오리지널 제품 대신 레즈보글라를 사용할 수 있도록 했습니다.
또한, 2021년 7월 미국 식품의약국(FDA)은 최초의 상호교환 가능한 바이오시밀러 인슐린 제품인 셈글리(인슐린 글라진-yfgn)를 승인했습니다. 셈글리는 오리지널 제품인 란투스(인슐린 글라진)와 생물학적으로 유사하며 상호교환 가능한 장기 지속형 인슐린 유사체로, 제1형 당뇨병 성인 및 소아 환자와 제2형 당뇨병 성인 환자의 혈당 조절 개선에 사용됩니다.
지역 분석
북미 시장, 세계 시장 주도 예상
북미 시장은 비용 효율적인 인슐린 생산을 위한 노력 증가와 시장 개발 확대로 인해 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 캘리포니아 주지사는 최근 2022년과 2023년 주 예산에 주 내 인슐린 접근성 및 가격 경쟁력 향상을 위한 저비용 인슐린 개발에 1억 달러를 편성했습니다. 예산에는 2022-2023년 CalRX 바이오시밀러 인슐린 이니셔티브에 1억 70만 달러가 포함되었으며, 2023-2024년과 2025-2026년 사이에는 매년 70만 달러씩 지원될 예정입니다.
예산 중 5천만 달러는 저비용의 상호 교환 가능한 바이오시밀러 인슐린 개발 확장에, 5천만 달러는 캘리포니아에 인슐린 제조 시설 설립에, 그리고 70만 달러는 주 정부 운영에 매년 지원될 예정입니다. 또한, 2023년 9월, 시카고에 본사를 둔 완전 법인 형태의 바이오제약 회사인 메이시얼 파마슈티컬스(Meitheal Pharmaceuticals)는 퉁화동바오제약(Tonghua Dongbao Pharmaceutical)과 인슐린 아스파트, 인슐린 리스프로, 인슐린 글라진 등 세 가지 인슐린 바이오시밀러를 미국에서 상용화하기 위한 독점 라이선스 계약을 체결했습니다. NKF는 계열사인 THDB로부터 이 세 가지 조합에 대한 개발 및 상용화 권한을 모두 보유하며, 메이시얼은 미국에서 이러한 개발을 상용화할 계획입니다.

COVID-19 영향 분석
COVID-19 감염 증상이 나타나는 당뇨병 환자는 심각한 합병증 발생 위험이 더 높았습니다. 따라서 이들에게는 잦은 혈당 모니터링, 건강한 식단, 충분한 수분 섭취, 그리고 혈당 강하제 용량 조절이 필요했습니다. 그러나 인슐린 치료는 COVID-19에 감염된 당뇨병 환자의 인공호흡기 사용 필요성과 사망률을 증가시킬 수 있으며, 이는 팬데믹 기간 동안 인슐린 바이오시밀러의 다국적 시장 위축을 초래했습니다.

시장 세분화
제품별
• 장기지속형 바이오시밀러
• 속효성 바이오시밀러
• 프리믹스 바이오시밀러
적응증별
• 제1형 당뇨병
• 제2형 당뇨병
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2022년 11월, Biocon Ltd.의 계열사인 Biocon Biologics Ltd.는 파트너사인 Viatris Inc.의 다국적 바이오시밀러 사업 부문을 인수했습니다. Biocon Biologics와 Viatris는 필수적인 다국적 기업으로부터 모든 관련 허가를 획득했습니다. 미국 연방거래위원회(FTC), 인도 경쟁위원회(CCI), 인도 중앙은행(RBI)을 포함한 규제 기관 및 투자자들이 주요 이해관계자입니다.
• 2021년 10월, 산도즈(Sandoz)는 중국 간앤리(Gan & Lee)와 협력하여 3가지 바이오시밀러 인슐린 제품 개발을 진행 중이며, 란투스(인슐린 글라진) 바이오시밀러 후보 물질에 대한 3상 임상시험을 완료했습니다.

• 2020년 5월, 유럽 의약품청(EMA) 산하 인체용 의약품 위원회(CHMP)는 사노피(Sanofi)가 개발한 당뇨병 치료용 바이오시밀러 인슐린 아스파트에 대한 판매 허가를 승인했습니다.

경쟁 환경
주요 글로벌 시장 참여 기업으로는 베링거인겔하임(Boehringer Ingelheim), 화이자(Pfizer Inc.), 바이오콘(Biocon), 머크(Merck & Co.), 일라이 릴리(Eli Lilly & Co.), 노보 노르디스크(NOVO Nordisk A/S), 사노피(Sanofi S.A.), 입소메드(Ypsomed AG), 암파스타 파마슈티컬스(Amphastar Pharmaceuticals, Inc.), 줄파 걸프 파마슈티컬 인더스트리즈(Julphar Gulf Pharmaceutical Industries) 등이 있습니다.
보고서 구매 이유

• 제품, 적응증, 유통 채널 및 지역별 글로벌 인슐린 바이오시밀러 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 인슐린 바이오시밀러 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 인슐린 바이오시밀러 시장 보고서는 약 61개의 표, 56개의 그림, 180페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global insulin biosimilars market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Biosimilars are equivalent to a reference biologic drug and are developed after the patent on the concerned biologic drug has passed. Biosimilar insulin is a biological replica of an actual insulin and there is rising interest in designing and utilizing them. Biosimilar insulins are more inexpensive compared to original developments therefore they offer the NHS with prospects around availability and expense of care.
Market Dynamics: Drivers & Restraints
Increasing Cases of Diabetes
The global market growth is expected to be boosted during the forecast period due to the increasing cases of diabetes mellitus. The World Health Organization (WHO) states that about 422 million individuals worldwide have diabetes, the bulk of whom are living in low- and middle-income countries, and over 1.5 million casualties are straight attributed to diabetes annually. Both the number of cases and the preponderance of diabetes have been steadily growing over the past few decades. Moreover, according to the International Diabetes Federation, IDF projections by 2045, one in eight adults, roughly 783 million individuals are expected to be living with diabetes, an upsurge of 46%. Above 90% of individuals with diabetes have type 2 diabetes, which is caused by socio-economic, demographic, environmental, and genetic factors. Again, Diabetes Australia identifies diabetes as the fastest-growing chronic disorder globally. The number of individuals with type 2 diabetes is increasing in each nation, and in 2021, diabetes induced 6.7 million casualties globally.
Additionally, the growing geriatric population and increased research activities are among the additional factors boosting the global market during the forecast period.
Insulin Side Effects
However, the global market growth for insulin biosimialr is being hindered during the forecast period owing to its side effects. The typical side effects of insulin include hypoglycemia (low blood glucose), injection site allergies, and weight increase. Infrequent side effects of insulin include lipodystrophy (abnormal fat distribution) and swelling in the arms and legs. Further, the presence of stringent regulatory bodies and high therapy cost are among the additional factors slowing the global market growth during the forecast period.
For more details on this report – Request for Sample
Segment Analysis
The global insulin biosimilars market is segmented based on product, indication, distribution channel and region.
Long-Acting Insulin Biosimilars Product Type Segment is Expected to Dominate Market
During the forecast period, the segment of long-acting insulin biosimilars is expected to dominate the global market, due to the increasing product introduction and approval. For example, Eli Lilly and Company introduced its insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), on the US market in April 2023, making it the second interchangeable insulin biosimilar to become commercially obtainable to American patients with diabetes. Moreover, in November 2022, The FDA approved Rezvoglar, a biosimilar for Lantus (insulin glargine) that was originally approved in December 2021, for an interchangeability designation, letting the product to be swapped for the reference product at the pharmacy station without needing physician permission.
Additionally, in July 2021, the US Food and Drug Administration approved the first interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), which is both biosimilar to and interchangeable with its reference product Lantus (insulin glargine), a long-acting insulin analog, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.
Geographical Analysis
North America is Expected to Dominate the Global Market
The North America market is expected to dominate the global market during the forecast period due to rising initiatives to produce cost-effective insulin and increasing market developments. For instance, California's governor lately marked the state's budget for 2022 and 2023, which included a $100 million budget for designing low-cost insulin to improve availability and affordability of insulin in the state. The budget included $100.7 million for the CalRX Biosimilar Insulin Initiative in 2022-2023, heeded by $700,000 yearly between 2023-2024 and 2025-2026.
Of the budget, $50 million intended move to the expansion of low-cost interchangeable biosimilar insulin developments, $50 million to an insulin manufacturing establishment established in California, and $700,000 yearly to state operations. Furthermore, in September 2023, Meitheal Pharmaceuticals, a fully incorporated biopharmaceutical corporation based in Chicago, formed an exclusive licensing deal with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars - insulin aspart, insulin lispro, and insulin glargine in the US. NKF has undivided development and commercial privileges for the three combinations from associate THDB and plans for Meitheal to commercialize such developments in the US.
COVID-19 Impact Analysis
Patients with diabetes who develop symptoms of COVID-19 infection were at a more elevated threat of adverse consequences. Thus, they needed frequent glucose monitoring, a healthy diet, satisfactory hydration, and dose titration of glucose-lowering drugs. However, insulin therapy may raise the requirement for mechanical ventilation and the mortality rate in diabetic patients with COVID-19, which diminished the multinational market for insulin biosimilars during the pandemic.
Market Segmentation
By Product
• Long Acting Biosimilars
• Rapid Acting Biosimilars
• Premixed Biosimilars
By Indication
• Type 1 Diabetes
• Type 2 Diabetes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In November 2022, Biocon Biologics Ltd., an associate of Biocon Ltd. completed the acquisition of the multinational biosimilars business of its partner Viatris Inc. Biocon Biologics and Viatris have acquired all relevant permissions from essential multinational regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors.
• In October 2021, Sandoz’ association with China’s Gan & Lee covering three biosimilar insulin products persists to create advancement, with the closing of a couple of Phase III trials concerning a suggested biosimilar to Lantus (insulin glargine).
• In May 2020, the Committee for Medicinal Products for Human Use (CHMP) Europe granted marketing authorization for a biosimilar insulin aspart formulated by Sanofi and planned for the therapy of diabetes mellitus.
Competitive Landscape
The major global players in the market include Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Eli Lilly & Co., NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG, Amphastar Pharmaceuticals, Inc. and Julphar Gulf Pharmaceutical Industries.
Why Purchase the Report?
• To visualize the global insulin biosimilars market segmentation based on product, indication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of insulin biosimilars market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.
The global insulin biosimilars market report would provide approximately 61 tables, 56 figures and 180 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Indication
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Cases of Diabetes
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Insulin Side Effects
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Pipeline Analysis
5.6. Unmet Need
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Long Acting Biosimilars*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Rapid Acting Biosimilars
7.4. Premixed Biosimilars
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Type 1 Diabetes*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Type 2 Diabetes
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Boehringer Ingelheim*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer Inc.
12.3. Biocon, Inc.
12.4. MERCK & CO.
12.5. Eli Lilly & Co.
12.6. NOVO Nordisk A/S
12.7. Sanofi S.A.
12.8. Ypsomed AG
12.9. Amphastar Pharmaceuticals, Inc.
12.10. Julphar Gulf Pharmaceutical Industries
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Boehringer Ingelheim, 4.	Key Developments, Pfizer Inc., Biocon, Inc., MERCK & CO., Eli Lilly & Co., NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG, Amphastar Pharmaceuticals, Inc., Julphar Gulf Pharmaceutical Industries

표 목록 (Tables)

List of Tables

Table 1 Global Insulin Biosimilars Market Value, By Product, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Insulin Biosimilars Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Insulin Biosimilars Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Insulin Biosimilars Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Insulin Biosimilars Market Value, By Product, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Insulin Biosimilars Market Value, By Product, 2021-2030 (US$ Million)

Table 7 Global Insulin Biosimilars Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Insulin Biosimilars Market Value, By Indication, 2021-2030 (US$ Million)

Table 9 Global Insulin Biosimilars Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Insulin Biosimilars Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Insulin Biosimilars Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Insulin Biosimilars Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Insulin Biosimilars Market Value, By Product, 2021-2030 (US$ Million)

Table 14 North America Insulin Biosimilars Market Value, By Indication, 2021-2030 (US$ Million)

Table 15 North America Insulin Biosimilars Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Insulin Biosimilars Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Insulin Biosimilars Market Value, By Product, 2021-2030 (US$ Million)

Table 18 South America Insulin Biosimilars Market Value, By Indication, 2021-2030 (US$ Million)

Table 19 South America Insulin Biosimilars Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Insulin Biosimilars Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Insulin Biosimilars Market Value, By Product, 2021-2030 (US$ Million)

Table 22 Europe Insulin Biosimilars Market Value, By Indication, 2021-2030 (US$ Million)

Table 23 Europe Insulin Biosimilars Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Insulin Biosimilars Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Insulin Biosimilars Market Value, By Product, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Insulin Biosimilars Market Value, By Indication, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Insulin Biosimilars Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Insulin Biosimilars Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Insulin Biosimilars Market Value, By Product, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Insulin Biosimilars Market Value, By Indication, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Insulin Biosimilars Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Boehringer Ingelheim: Overview

Table 33 Boehringer Ingelheim: Product Portfolio

Table 34 Boehringer Ingelheim: Key Developments

Table 35 Pfizer Inc.: Overview

Table 36 Pfizer Inc.: Product Portfolio

Table 37 Pfizer Inc.: Key Developments

Table 38 Biocon, Inc.: Overview

Table 39 Biocon, Inc.: Product Portfolio

Table 40 Biocon, Inc.: Key Developments

Table 41 MERCK & CO.: Overview

Table 42 MERCK & CO.: Product Portfolio

Table 43 MERCK & CO.: Key Developments

Table 44 Eli Lilly & Co.: Overview

Table 45 Eli Lilly & Co.: Product Portfolio

Table 46 Eli Lilly & Co.: Key Developments

Table 47 NOVO Nordisk A/S: Overview

Table 48 NOVO Nordisk A/S: Product Portfolio

Table 49 NOVO Nordisk A/S: Key Developments

Table 50 Sanofi S.A.: Overview

Table 51 Sanofi S.A.: Product Portfolio

Table 52 Sanofi S.A.: Key Developments

Table 53 Ypsomed AG: Overview

Table 54 Ypsomed AG: Product Portfolio

Table 55 Ypsomed AG: Key Developments

Table 56 Amphastar Pharmaceuticals, Inc.: Overview

Table 57 Amphastar Pharmaceuticals, Inc.: Product Portfolio

Table 58 Amphastar Pharmaceuticals, Inc.: Key Developments

Table 59 Julphar Gulf Pharmaceutical Industries: Overview

Table 60 Julphar Gulf Pharmaceutical Industries: Product Portfolio

Table 61 Julphar Gulf Pharmaceutical Industries: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 2 Global Insulin Biosimilars Market Share, By Product, 2022 & 2030 (%)

Figure 3 Global Insulin Biosimilars Market Share, By Indication, 2022 & 2030 (%)

Figure 4 Global Insulin Biosimilars Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Insulin Biosimilars Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Insulin Biosimilars Market Y-o-Y Growth, By Product, 2022-2030 (%)

Figure 7 Long Acting Biosimilars Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 8 Rapid Acting Biosimilars Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 9 Premixed Biosimilars Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 10 Global Insulin Biosimilars Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 11 Type 1 Diabetes Indication in Global Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 12 Type 2 Diabetes Indication in Global Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 13 Global Insulin Biosimilars Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 14 Hospital Pharmacies Distribution Channel in Global Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 15 Retail Pharmacies Distribution Channel in Global Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 16 Online Pharmacies Distribution Channel in Global Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 17 Global Insulin Biosimilars Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 18 North America Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 19 Asia-Pacific Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 20 Europe Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 21 South America Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 22 Middle East and Africa Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 23 North America Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 24 North America Insulin Biosimilars Market Share, By Product, 2022 & 2030 (%)

Figure 25 North America Insulin Biosimilars Market Share, By Indication, 2022 & 2030 (%)

Figure 26 North America Insulin Biosimilars Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 27 North America Insulin Biosimilars Market Share, By Country, 2022 & 2030 (%)

Figure 28 South America Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 29 South America Insulin Biosimilars Market Share, By Product, 2022 & 2030 (%)

Figure 30 South America Insulin Biosimilars Market Share, By Indication, 2022 & 2030 (%)

Figure 31 South America Insulin Biosimilars Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32 South America Insulin Biosimilars Market Share, By Country, 2022 & 2030 (%)

Figure 33 Europe Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 34 Europe Insulin Biosimilars Market Share, By Product, 2022 & 2030 (%)

Figure 35 Europe Insulin Biosimilars Market Share, By Indication, 2022 & 2030 (%)

Figure 36 Europe Insulin Biosimilars Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 Europe Insulin Biosimilars Market Share, By Country, 2022 & 2030 (%)

Figure 38 Asia-Pacific Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 39 Asia-Pacific Insulin Biosimilars Market Share, By Product, 2022 & 2030 (%)

Figure 40 Asia-Pacific Insulin Biosimilars Market Share, By Indication, 2022 & 2030 (%)

Figure 41 Asia-Pacific Insulin Biosimilars Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Asia-Pacific Insulin Biosimilars Market Share, By Country, 2022 & 2030 (%)

Figure 43 Middle East & Africa Insulin Biosimilars Market Value, 2021-2030 (US$ Million)

Figure 44 Middle East & Africa Insulin Biosimilars Market Share, By Product, 2022 & 2030 (%)

Figure 45 Middle East & Africa Insulin Biosimilars Market Share, By Indication, 2022 & 2030 (%)

Figure 46 Middle East & Africa Insulin Biosimilars Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 Boehringer Ingelheim: Financials

Figure 48 Pfizer Inc.: Financials

Figure 49 Biocon, Inc.: Financials

Figure 50 MERCK & CO.: Financials

Figure 51 Eli Lilly & Co.: Financials

Figure 52 NOVO Nordisk A/S: Financials

Figure 53 Sanofi S.A.: Financials

Figure 54 Ypsomed AG: Financials

Figure 55 Amphastar Pharmaceuticals, Inc.: Financials

Figure 56 Julphar Gulf Pharmaceutical Industries: Financials

글로벌 인슐린 바이오시밀러 시장 – 2023-2030

Global Insulin Biosimilars Market - 2023-2030